Abstract

Abundant, Ultra-Short Trans-Renal Tumor DNA Fragments in Urine For Non-Invasive Cancer Detection and Monitoring

Qing Kang, Senior Scientist, Syros Pharmaceuticals, Inc.

Circulating tumor DNA (ctDNA) has shown great promise as a cancer biomarker in detecting tumor genotypes, monitoring cancer recurrence and resistance, as well as assessing treatment response. Compared to increased studies in plasma ctDNA, trans-renal tumor DNA (trDNA) exists as a largely untapped field. Here we present a proof-of-concept study to comprehensively understand the fundamentals of trDNA in different cohorts of cancer patients.